SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

LYTIX (LYTIX) News

Follow LYTIX (LYTIX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol LYTIX Asset market Sector Markets 90 days 4 Updated Aug 28, 2026, 04:24 PM UTC Open live news feed
H FDA clears Phase III path for Lytix ruxotemitide FDA cleared the Phase III development path for ruxotemitide in Lytix Biopharma’s program. REGULATION | Aug 28, 2026, 04:24 PM UTC M Lytix wins FDA approval for phase III melanoma trial FDA approval for a phase III melanoma trial clears a path for partnership focus at Lytix. REGULATION | Aug 27, 2026, 01:28 PM UTC M Lytix gets FDA clearance for registrational Phase III melanoma path Lytix says the FDA cleared its registrational Phase III path in melanoma. REGULATION | Aug 27, 2026, 12:58 PM UTC M Lytix gets FDA Phase III clearance for ruxotemitide FDA cleared Phase III for ruxotemitide. Lytix says its cash position supports advancing the clinical pipeline. REGULATION | Aug 27, 2026, 05:04 AM UTC